Nicotinamide mononucleotide as a therapeutic agent to alleviate multi-organ failure in sepsis
Ting Cao, Rui Ni, Weimin Ding, Xiaoyun Ji, Guo-Chang Fan, Zhuxu Zhang, Tianqing Peng · 2023
Read Nicotinamide mononucleotide as a therapeutic agent to alleviate multi-organ failure in sepsis by Ting Cao, Rui Ni, Weimin Ding, Xiaoyun Ji, Guo-Chang Fan, Zhuxu Zhang, Tianqing Peng (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10699070.txt.
Description
Ting Cao and six co-authors tested a vitamin-related compound as a treatment for the organ failure of sepsis, in this 2023 study. Sepsis, the body's runaway response to infection, remains a leading killer in intensive care, and no drug targets the failure of several organs at once. The compound, NMN, feeds production of NAD+, a molecule cells need for energy and repair, and early reports suggested it protects in sepsis.
In mice made septic by injecting feces into the abdomen, NMN given an hour later raised NAD+ levels and calmed the crisis across organs. Treated mice showed less oxidative stress, inflammation, and cell death, with better heart, lung, liver, and kidney function and lower death rates. Blood bacteria counts also fell. Lab tests on immune and vessel cells helped trace how the compound works. The study builds a case for testing NMN in human sepsis.
Catalog record
| CREATOR | Ting Cao, Rui Ni, Weimin Ding, Xiaoyun Ji, Guo-Chang Fan, Zhuxu Zhang, Tianqing Peng |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |